PharmaCyte Biotech, Inc.
PMCB
$1.19
$0.043.48%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.07% | -11.15% | -17.43% | 2.10% | -8.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.04% | -8.92% | -16.59% | 1.00% | -11.37% |
| Operating Income | 28.04% | 8.92% | 16.59% | -1.00% | 11.37% |
| Income Before Tax | 1,877.84% | 1,866.55% | 552.43% | 107.73% | 79.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1,877.84% | 1,866.55% | 552.43% | 107.73% | 79.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,877.84% | 1,866.55% | 552.43% | 107.73% | 79.70% |
| EBIT | 28.04% | 8.92% | 16.59% | -1.00% | 11.37% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 184.54% | 220.45% | 243.26% | -723.11% | -434.84% |
| Normalized Basic EPS | 10,358.33% | 4,575.65% | 307.69% | 285.34% | 95.06% |
| EPS Diluted | 184.54% | 220.45% | 243.26% | -723.11% | -434.84% |
| Normalized Diluted EPS | 10,358.33% | 4,575.65% | 307.69% | 285.34% | 95.06% |
| Average Basic Shares Outstanding | -35.50% | -44.19% | -52.01% | -51.00% | -41.65% |
| Average Diluted Shares Outstanding | -35.50% | -44.19% | -52.01% | -51.00% | -41.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |